Skip to main content

Table 1 Characteristics of patients included in this study

From: Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer

Characteristics No. of patients/No. of all patients Percentage
No. of patients 7425/7425 100.0%
Average Median Age (range) 65.1 (25 to 87)  
Sex
 Male 3955/6912 57.2%
 Female 2957/6912 42.8%
ECOG score
 0–1 4496/5083 88.5%
 2+ 587/5083 11.5%
Site
 Head or neck 1895/4209 45.0%
 Body or tail 2037/4209 48.4%
 Other* 277/4209 6.6%
Metastatic diseases 6684/7425 90.0%
Metastatic sites
 Liver 1825/3213 56.8%
 Lymph nodes 511/3213 15.9%
 Peritoneal 572/3213 17.8%
 Lung 446/3213 13.9%
 Other 401/3213 12.5%
Treatments
 FOLFIRINOX 2659/6351 41.9%
 GEM-NAB 1929/6351 30.4%
 GEM 1420/6351 22.4%
 mFOLFIRINOX 343/6351 5.4%
  1. Abbreviations: No.: number; ECOG: Eastern Cooperative Oncology Group; GEM: gemcitabine; GEM-NAB: Gemcitabine plus nab-paclitaxel; FOLFIRINOX: the combination of 5-fluorouracil, oxaliplatin, and irinotecan; mFOLFIRINOX: at least one of the drugs was reduced and/or the removal of 5-FU bolus in FOLFIRINOX
  2. * Including the cancers involved multiple sites or those originating from unknown subsites of pancreas